Small molecule drug pipelines remain strong, but large molecule therapeutics are gaining momentum among biotechnology and pharmaceutical companies.

Tolland, CT (April 22, 2008) – Nerac Inc., a research and advisory firm for companies developing innovative products and technologies, today released a white paper titled “New Perspectives on the Future of Drug Discovery” that looks at what is in the pipeline for biotechnology and pharmaceutical companies. The paper demonstrates how Nerac’s novel analytics can help overcome information paralysis created by constantly changing, overwhelmingly complex and voluminous data to help companies to make timely, profitable decisions.

The white paper uses a case study that the authors constructed to measure large and small molecule drug pipeline trends among the pharmaceutical companies Pfizer, AstraZeneca, and Sanofi-Adventis, and the biotechnology companies Amgen, Genentech, and Genzyme. The objective was to independently analyze data from patent and non-patent sources, to determine common and uncommon conclusions about small and large molecule drug development, and to illustrate novel macro-analysis and visualization techniques to effectively analyze complex data.

Key Findings:

• While non-patent data indicates pharmaceutical companies are moving aggressively into large molecule drug development, patent data suggests a more measured approach.
• The case study biotechnology companies lead large molecule development, but the pharmaceutical companies are strong contenders.
• The biotechnology companies were more aggressive filing patent applications for small molecule therapeutics than pharmaceutical companies were for large molecule therapeutics, though the pharmas continue to dominate small molecule development.
• Both small and large molecule therapeutics will find future applications in inflammation and cancer therapies.
• Small molecule drugs will continue to dominate central nervous system and infectious disease treatments.
• Based on market value projections, small molecule drugs will continue to dominate the market for the foreseeable future.

To download the white paper, please click here.

About Nerac

Nerac Inc., based in Tolland, CT, is a research and advisory firm for companies developing innovative products and technologies. Nerac Analysts deliver custom assessments of product and technology development opportunities, competitor intelligence, intellectual property strategies, and compliance requirements through a proven blended approach to custom analysis: review of technical knowledge, investigation of intellectual property, and appraisal of business impacts. Nerac deploys analysts in diverse disciplines to help clients discover new applications, serving as a catalyst for new thinking and creative approaches to business problems or identifying strategic growth opportunities. On the web at www.nerac.com.

Contact:

Richard Urban
Business/Marketing Editor
Nerac, Inc.
One Technology Drive
Tolland, CT 06084
860-872-7000, ext. 1061
rurban@nerac.com
www.nerac.com